Cantaron, France

Jean-Francois Peyron



Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jean-Francois Peyron

Introduction

Jean-Francois Peyron is a notable inventor based in Cantaron, France. He has made significant strides in the field of cancer treatment through his innovative research and development. His work focuses on creating effective therapeutic solutions for patients in need.

Latest Patents

Jean-Francois Peyron holds a patent for an anticancer agent composition. This patent outlines a method for treating cancer that involves administering an anticancer agent composition containing a LAT1 inhibitor and various other active ingredients. These ingredients include alkylating agents, platinum-based antineoplastic agents, anti-metabolites, topoisomerase inhibitors, anti-microtubule polymerizing agents, hormonal agents, anti-microtubule depolymerizing agents, anticancer antibiotics, and molecular targeted agents. This innovative approach aims to enhance the efficacy of cancer treatments.

Career Highlights

Throughout his career, Peyron has demonstrated a commitment to advancing medical science. His work at J-Pharma Co., Ltd. has positioned him as a key player in the pharmaceutical industry. His dedication to research and development has led to breakthroughs that could potentially improve the lives of many cancer patients.

Collaborations

Jean-Francois Peyron has collaborated with esteemed colleagues such as Hitoshi Endou and Michael Fitzpatrick Wempe. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jean-Francois Peyron's contributions to cancer treatment through his patented anticancer agent composition highlight his role as an influential inventor. His work continues to inspire advancements in medical research and offers hope for improved cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…